维拉帕米和仙茅苷在大鼠体内药物相互作用研究

目的：研究维拉帕米联用仙茅苷之后，维拉帕米和仙茅苷在大鼠体内可能发生的药物相互作用。方法：24只雄性SD大鼠，随机分为单药组和联用药组，单药组灌胃仙茅苷20 mg· kg-1，联用药组灌胃维拉帕米和仙茅苷，其给药剂量分别为10 mg·kg-1和20 mg·kg-1。在不同时间点取血，采用LC-MS测定仙茅苷的的血药浓度，计算并比较仙茅苷的药代动力学参数。结果：与单药组相比，联用药组仙茅苷药代动力学参数发生明显变化，其中仙茅苷最大血药浓度从189.13 ng·mL-1增加到277.53 ng·mL-1，血浆曲线下面积从949.18 ng·h·mL-1增加到1728.08 ng·h·mL-1。结论：维拉帕米联合仙茅苷用药之后，维拉帕米能明显增强仙茅苷在大鼠体内的血药浓度。

Interaction between Verapamil and Curculigoside in Rats

Objective: To investigate potential interaction between verapamil and curculigoside. Meth-ods: Twenty-four rats were randomized to two groups (twelve rats in each group), including the curculigo-side-only group (A) and the curculigoide and verapamil group (B). Animals in group A were administered oral curculigoside at 20 mg·kg-1; and animals in group B were administered oral curculigoside (20 mg·kg-1) and verapamil (10 mg·kg-1). Blood samples were collected at different time points after drug administration, and the plasma concentrations of curculigoside were determined using LC-MS. Finally the pharmacokinetic profiles of curculigoside were calculated and compared. Results: The results indicated that verapamil could significantly change the pharmacokinetic profiles of curculigoside in rats. Verapamil could significantly in-crease the peak plasma concentration (from 189.13 ng·mL-1 to 277.53 ng·mL-1) and AUC0-t (from 949.18 ng· h·mL-1 to 1728.08 ng·h·mL-1) of curculigoside. Conclusion: The results indicatedthat verapamil could sig-nificantly increase the plasma concentration of curculigoside when verapami and curculigside were concomi-tantly administered.